<SEC-DOCUMENT>0001193125-26-215683.txt : 20260511
<SEC-HEADER>0001193125-26-215683.hdr.sgml : 20260511
<ACCEPTANCE-DATETIME>20260511071016
ACCESSION NUMBER:		0001193125-26-215683
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		11
CONFORMED PERIOD OF REPORT:	20260511
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20260511
DATE AS OF CHANGE:		20260511

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Apogee Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001974640
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				934958665
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41740
		FILM NUMBER:		26960841

	BUSINESS ADDRESS:	
		STREET 1:		221 CRESCENT ST.
		STREET 2:		BUILDING 17, SUITE 102B
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02453
		BUSINESS PHONE:		650-394-5230

	MAIL ADDRESS:	
		STREET 1:		221 CRESCENT ST.
		STREET 2:		BUILDING 17, SUITE 102B
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02453

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Apogee Therapeutics, LLC
		DATE OF NAME CHANGE:	20230420
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>apge-20260511.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2026-05-08T18:34:18.4084+00:00 -->
<!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:apge="http://apogeetherapeutics.com/20260511" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16">
 <head>
  <title>8-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_d0a1e764-9a17-4f00-8f05-631b4565e9d3" name="dei:AmendmentFlag" contextRef="C_563d7b72-ba59-4de2-b514-45cfd636ff13">false</ix:nonNumeric><ix:nonNumeric id="F_61880498-ac0b-405e-af83-3c95a0940da2" name="dei:EntityCentralIndexKey" contextRef="C_563d7b72-ba59-4de2-b514-45cfd636ff13">0001974640</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="apge-20260511.xsd"/></ix:references><ix:resources><xbrli:context id="C_563d7b72-ba59-4de2-b514-45cfd636ff13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001974640</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2026-05-11</xbrli:startDate><xbrli:endDate>2026-05-11</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.2in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="border-top:2.25pt double #000000;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">UNITED STATES<br/>SECURITIES AND EXCHANGE COMMISSION<br/></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WASHINGTON, D.C. 20549</span></p><p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><h2 style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FORM </span><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7db95f53-4e14-4362-b020-2680a1b81e62" contextRef="C_563d7b72-ba59-4de2-b514-45cfd636ff13" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8-K</span></ix:nonNumeric></span></h2><p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CURRENT REPORT</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:100%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;margin-right:0.398%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Date of Report (Date of earliest event reported): </span><span><ix:nonNumeric id="F_13b1fdab-e37e-42f6-8478-cc0408faaca2" contextRef="C_563d7b72-ba59-4de2-b514-45cfd636ff13" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">May 11, 2026</span></ix:nonNumeric></span></p></td>
    </tr>
   </table><p style="margin-left:40%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:24pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e62ed8a6-c383-456a-a54a-e231451a5a4f" contextRef="C_563d7b72-ba59-4de2-b514-45cfd636ff13" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:24pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Apogee Therapeutics, Inc.</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Exact name of Registrant as Specified in Its Charter)</span></p><p style="margin-left:40%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:20%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:20%;box-sizing:content-box;"/>
     <td style="width:18%;box-sizing:content-box;"/>
     <td style="width:41%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_bb188c47-2196-482e-aa24-a048cda6a289" contextRef="C_563d7b72-ba59-4de2-b514-45cfd636ff13" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_3100d4af-a6ee-4102-8580-0cd1d895d87c" contextRef="C_563d7b72-ba59-4de2-b514-45cfd636ff13" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">001-41740</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_e5231239-9761-4694-a239-294cbc88013e" contextRef="C_563d7b72-ba59-4de2-b514-45cfd636ff13" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">93-4958665</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(State or Other Jurisdiction<br/>of Incorporation)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Commission File Number)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(IRS Employer<br/>Identification No.)</span></p></td>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_156fc5e4-b632-40ae-ae94-681b9b4e097c" contextRef="C_563d7b72-ba59-4de2-b514-45cfd636ff13" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">221 Crescent St., Bldg 17, Suite 102b</span></ix:nonNumeric></span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_c1881a8b-3e3a-46f8-a399-ef8707fed918" contextRef="C_563d7b72-ba59-4de2-b514-45cfd636ff13" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Waltham</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_e915b689-9973-4c1b-b372-86fdc652bb47" contextRef="C_563d7b72-ba59-4de2-b514-45cfd636ff13" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Massachusetts</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_7cbd1851-33c7-4283-ba1a-28b8380f99dd" contextRef="C_563d7b72-ba59-4de2-b514-45cfd636ff13" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">02453</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Address of Principal Executive Offices)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Zip Code)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:100%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.125in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.398%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Registrant&#8217;s Telephone Number, Including Area Code:</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span><span><ix:nonNumeric id="F_b40407a7-1fda-4260-8e72-fff126564c95" contextRef="C_563d7b72-ba59-4de2-b514-45cfd636ff13" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(650)</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span><span><ix:nonNumeric id="F_2358b1b4-e015-400a-a551-997d197a6878" contextRef="C_563d7b72-ba59-4de2-b514-45cfd636ff13" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">394-5230</span></ix:nonNumeric></span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:100%;box-sizing:content-box;"/>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.125in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Former Name or Former Address, if Changed Since Last Report)</span></p><p style="margin-left:40%;font-size:10pt;margin-top:9.35pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:justify;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3aaab9bc-9fb4-43e2-a768-42fc66cdac54" contextRef="C_563d7b72-ba59-4de2-b514-45cfd636ff13" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:justify;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9dd67022-5176-40e9-b068-e27b3a226e42" contextRef="C_563d7b72-ba59-4de2-b514-45cfd636ff13" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:justify;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_43f47158-4d39-43f6-afaf-5e0e22cb0af7" contextRef="C_563d7b72-ba59-4de2-b514-45cfd636ff13" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div><div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:justify;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3e4e1819-96c3-4abe-95e1-1dc4a37a917b" contextRef="C_563d7b72-ba59-4de2-b514-45cfd636ff13" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:38%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:15%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:45%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><br/>Title of each class</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Trading<br/>Symbol(s)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><br/>Name of each exchange on which registered</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_8df06f55-0fcc-417b-8fd3-fc17a3eb4e5a" contextRef="C_563d7b72-ba59-4de2-b514-45cfd636ff13" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common Stock, par value $0.00001 per share</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_2a877d00-c05f-470d-814b-37b5795b06f1" contextRef="C_563d7b72-ba59-4de2-b514-45cfd636ff13" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">APGE</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_e67cf48a-d427-4747-ade9-7af47c933ad3" contextRef="C_563d7b72-ba59-4de2-b514-45cfd636ff13" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">The Nasdaq Global Market</span></ix:nonNumeric></span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8239;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#8239;240.12b-2 of this chapter).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Emerging growth company </span><span style="font-size:10pt;"><ix:nonNumeric id="F_ac35f3a5-56cc-4038-9f5b-25ad952f1f89" contextRef="C_563d7b72-ba59-4de2-b514-45cfd636ff13" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double #000000;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.2in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><h2 style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 2.02 	Results of Operations and Financial Condition.</span></h2><h2 style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></h2><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On May 11, 2026, Apogee Therapeutics, Inc. (the &#8220;Company&#8221;) issued a press release providing a business update and announcing its financial results for the quarter ended March 31, 2026 (the &#8220;Earnings Press Release&#8221;).</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A copy of the Earnings Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K (the &#8220;Form 8-K&#8221;) and is incorporated by reference herein. The exhibit furnished under Item 2.02 of this Form 8-K shall not be deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), regardless of any general incorporation language in such filing.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:14%;box-sizing:content-box;"/>
     <td style="width:86%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Item 9.01</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial Statements and Exhibits.</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d) </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Exhibits</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The following exhibits are being furnished herewith:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EXHIBIT INDEX</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:8.88%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:90.12%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit<br/>No.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Description</span></p></td>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">99.1</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="apge-ex99_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Earnings Press Release, dated May 11, 2026</span></a></p></td>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">104</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.2in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SIGNATURES</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:6%;box-sizing:content-box;"/>
     <td style="width:44%;box-sizing:content-box;"/>
     <td style="width:4%;box-sizing:content-box;"/>
     <td style="width:46%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:4.3pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Apogee Therapeutics, Inc.</span></p></td>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">May 11, 2026</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Michael Henderson, M.D.</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Michael Henderson, M.D.<br/>Chief Executive Officer</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>apge-ex99_1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2026-05-08T18:34:18.5690+00:00 --><!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-99.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div class="page" style="flex-direction:column;overflow:hidden;display:flex;min-height:11in;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.75in;width:7in;box-sizing:content-box;margin-right:auto;padding-right:0.75in;"><div class="absolute-block-container" style="margin-left:-0.75in;z-index:6;position:relative;"></div><div class="absolute-block-container" style="margin-left:-0.75in;z-index:4;position:relative;"></div><div class="absolute-block-container" style="margin-left:-0.75in;z-index:3;position:relative;"></div><div class="absolute-block-container" style="margin-left:-0.75in;z-index:1;position:relative;"><img src="img126220792_0.jpg" alt="img126220792_0.jpg" style="transform:translate(0px, 0px) rotate(0.0deg);z-index:257952768;overflow:hidden;top:0.0729in;left:6.8646in;width:1.5389in;position:absolute;height:0.5333in;"></div><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;">&#160;</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div><div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.75in;width:7in;box-sizing:content-box;margin-right:auto;padding-right:0.75in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Apogee Therapeutics Provides Pipeline Progress and Reports First Quarter 2026 Financial Results</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Zumilokibart advancing across multiple indications, with Phase 3 initiation in atopic dermatitis (AD) expected later this year:</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">- APEX Phase 2 Part A 52-week data demonstrated durable maintenance and improved efficacy over time with every 3- and 6-month dosing in moderate-to-severe AD</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">- APEX Phase 2 Part B 16-week data in AD expected in Q2 2026</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">- Following positive Phase 1b asthma results earlier this year, expansion plans are underway with additional trial details for asthma and eosinophilic esophagitis (EoE) expected later this year</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Strong cash position of $1.3B following successful public equity offering extending runway into 2029, through planned BLA filing for AD, subject to regulatory alignment</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">San Francisco and Boston, May 11, 2026</font><font style="color:#ff0000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x2013; Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with the potential for best-in-class profiles in the largest inflammatory and immunology (I&amp;I) markets, today provided pipeline progress and reported first quarter 2026 financial results.</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201c;We are off to a rapid start in 2026, reflecting the team&#x2019;s relentless focus on execution. Most notably, the APEX Phase 2 Part A 52-week results exceeded our expectations and reinforced the potentially best-in-class profile of zumilokibart as well as the central role of IL-13 as the master cytokine in AD. Zumilokibart demonstrated durable maintenance of response with 3- and 6-month dosing and improved efficacy of responses across all lesional and itch endpoints with meaningfully fewer doses than current therapies, representing a potentially transformational opportunity as a first-line product for AD patients,&#x201d; said Michael Henderson, M.D., Chief Executive Officer of Apogee Therapeutics. &#x201c;Based on these results, together with the positive Phase 1b asthma data shared in January 2026, we remain confident in the pipeline-in-a-product potential for zumilokibart and plan to outline broader expansion into asthma and EoE trials later this year. Following our recent successful financing, Apogee is well capitalized with cash runway into 2029, supporting advancement towards a BLA filing for AD and continued execution across our development programs, including the APEX Phase 2 Part B readout expected this quarter and initiation of our Phase 3 trials in AD expected later this year.&#x201d;</font></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Pipeline Progress, Corporate Highlights and Upcoming Milestones</font></p><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.7032428004023688%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">APEX Phase 2 Part A 52-week data for zumilokibart demonstrated durable maintenance and improved efficacy with every 3- and 6-month dosing in moderate-to-severe AD; APEX Phase 2 Part B 16-week data expected in Q2 2026:</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.5in;display:flex;margin-top:3pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.845698224151114%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">In March 2026, the company reported 52-week maintenance data evaluating 360mg of zumilokibart at 3- and 6-month intervals. At Week 52, durable maintenance of response was observed among Week 16 responders, as well as improved efficacy across the full treated population for all lesion and itch endpoints. Zumilokibart was well-tolerated with a safety profile consistent with other agents in the class. </font></div></div></div></div><div class="fixed-width-container" style="margin-left:auto;padding-left:0.75in;width:7in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.75in;"><div style="flex-grow:1;"></div><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="page" style="flex-direction:column;overflow:hidden;display:flex;min-height:11in;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.75in;width:7in;box-sizing:content-box;margin-right:auto;padding-right:0.75in;"><div class="absolute-block-container" style="margin-left:-0.75in;z-index:6;position:relative;"></div><div class="absolute-block-container" style="margin-left:-0.75in;z-index:4;position:relative;"></div><div class="absolute-block-container" style="margin-left:-0.75in;z-index:3;position:relative;"></div><div class="absolute-block-container" style="margin-left:-0.75in;z-index:1;position:relative;"><img src="img126220792_0.jpg" alt="img126220792_0.jpg" style="transform:translate(0px, 0px) rotate(0.0deg);z-index:257952768;overflow:hidden;top:0.0729in;left:6.8646in;width:1.5389in;position:absolute;height:0.5333in;"></div><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;">&#160;</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div><div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.75in;width:7in;box-sizing:content-box;margin-right:auto;padding-right:0.75in;"><div class="item-list-element-wrapper" style="margin-left:0.7999999999999998in;display:flex;margin-top:3pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.031793702227591%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Of patients that achieved EASI-75 at Week 16, 75% of patients with every 3-month dosing and 85% of patients with every 6-month dosing maintained response at Week 52.</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.7999999999999998in;display:flex;margin-top:3pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.031793702227591%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Of patients that achieved IGA 0/1 at Week 16, 86% of patients with every 3-month dosing and 78% of patients with every 6-month dosing maintained response at Week 52.</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.7999999999999998in;display:flex;margin-top:3pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.031793702227591%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Across the entire population treated with zumilokibart, responses improved through Week 52 for both every 3- and 6-month regimens, with IGA 0/1 of 72% and 52% at Week 52 improving up to 35% from Week 16, EASI-90 of 75% and 48% at Week 52 improving up to 36% from Week 16, and EASI-100 of 41% and 19% at Week 52 improving by up to 33% from Week 16, for every 3- and 6-month dosing, respectively.</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.5in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.845698224151114%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">At this year&#x2019;s American Academy of Dermatology (AAD) Annual Meeting, the company presented additional data including a late-breaking oral session, highlighting:</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.7999999999999998in;display:flex;margin-top:3pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.031793702227591%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Of patients who achieved EASI-90 at Week 16, 88% of patients with every 3-month dosing and 72% of patients with every 6-month dosing maintained such response at Week 52.</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.7999999999999998in;display:flex;margin-top:3pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.031793702227591%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Zumilokibart demonstrated improvements in lesional skin transcriptome across Type 1, 2, and 3 inflammatory pathways. </font></div></div><div class="item-list-element-wrapper" style="margin-left:0.5in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.845698224151114%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Part B of the APEX trial is designed to determine the optimized induction dose of zumilokibart, looking at low, medium (Part A dose), and high dose regimens vs. placebo. Results will determine the induction dosing regimen for the planned Phase 3 trials of zumilokibart, expected to initiate in the second half of 2026.</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.7032428004023688%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Completed $403 million upsized public equity offering: </font></div></div><div class="item-list-element-wrapper" style="margin-left:0.5in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.845698224151114%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Following the Phase 2 APEX Part A readout in March 2026, Apogee closed on an upsized public equity offering, including the full exercise of the underwriters&#x2019; option to purchase additional shares, with aggregate gross proceeds of approximately $403 million (before deducting underwriting discounts, commissions, and other offering expenses), which supports cash runway into 2029 through a planned BLA filing for zumilokibart in AD.</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.7032428004023688%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Zumilokibart demonstrated positive interim results from the Phase 1b trial in mild-to-moderate asthma in January 2026, reinforcing pipeline-in-a-product potential across I&amp;I indications: </font></div></div><div class="item-list-element-wrapper" style="margin-left:0.5in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.845698224151114%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">The company plans to provide further details on asthma and EoE trials for zumilokibart </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">later this </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">year. </font></div></div><div class="item-list-element-wrapper" style="margin-left:0.5in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.845698224151114%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Additional data from the Phase 1b asthma trial is expected to be shared at an upcoming medical conference.</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.7032428004023688%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Combination pipeline continues to advance across AD and respiratory indications for APG279 and APG273 with potential for improved efficacy and dosing:</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.5in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.845698224151114%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Phase 1b head-to-head study of APG279 (zumilokibart + APG990) versus DUPIXENT in AD is fully enrolled and expanded to 86 patients, with interim 24-week data expected in 2H 2026.</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.5in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.845698224151114%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Plans to advance APG273 (zumilokibart + APG333) in respiratory indications expected to be disclosed later this year.</font></div></div></div></div><div class="fixed-width-container" style="margin-left:auto;padding-left:0.75in;width:7in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.75in;"><div style="flex-grow:1;"></div><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="page" style="flex-direction:column;overflow:hidden;display:flex;min-height:11in;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.75in;width:7in;box-sizing:content-box;margin-right:auto;padding-right:0.75in;"><div class="absolute-block-container" style="margin-left:-0.75in;z-index:6;position:relative;"></div><div class="absolute-block-container" style="margin-left:-0.75in;z-index:4;position:relative;"></div><div class="absolute-block-container" style="margin-left:-0.75in;z-index:3;position:relative;"></div><div class="absolute-block-container" style="margin-left:-0.75in;z-index:1;position:relative;"><img src="img126220792_0.jpg" alt="img126220792_0.jpg" style="transform:translate(0px, 0px) rotate(0.0deg);z-index:257952768;overflow:hidden;top:0.0729in;left:6.8646in;width:1.5389in;position:absolute;height:0.5333in;"></div><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;">&#160;</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div><div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.75in;width:7in;box-sizing:content-box;margin-right:auto;padding-right:0.75in;"><div class="item-list-element-wrapper" style="margin-left:0.7999999999999998in;display:flex;margin-top:3pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.031793702227591%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Positive read-through from competitor proof-of-concept data in respiratory indications supports continued development of APG273. </font></div></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">First Quarter 2026 Financial Results</font></p><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.7032428004023688%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Cash Position</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">: Cash, cash equivalents, marketable securities and long-term marketable securities were $1.3 billion as of March 31, 2026, compared to $902.9 million as of December 31, 2025. Based on current operating plans, Apogee expects its existing cash, cash equivalents, marketable securities and long-term marketable securities will enable the company to fund its operating expenses into 2029.</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.7032428004023688%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">R&amp;D Expenses</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">: Research and development (R&amp;D) expenses were $60.8 million for the quarter ended March 31, 2026, compared to $46.4 million for the quarter ended March 31, 2025. R&amp;D expenses increased primarily driven by the continued development of our zumilokibart (APG777) and APG990/APG279 programs, increased external-discovery related costs, and higher personnel and equity-based compensation expenses associated with the growth in our research and development team, partially offset by decreases in expenses related to the APG333/APG273 program.</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.7032428004023688%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">G&amp;A Expenses</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">: General and administrative (G&amp;A) expenses were $22.0 million for the quarter ended March 31, 2026, compared to $16.7 million for the quarter ended March 31, 2025. G&amp;A expenses increased primarily due to increases in personnel-related expenses and equity-based compensation, primarily driven by increased headcount and an increase in the fair value of equity awards granted. These increases are the result of the company&#x2019;s expansion of operations to support the growth of its business.</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.7032428004023688%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Net Loss</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">: Net loss was $74.1 million for the quarter ended March 31, 2026, compared to a net loss of $55.3 million for the quarter ended March 31, 2025. Net loss increased primarily as a result of higher R&amp;D and G&amp;A expenses as described above.</font></div></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">About Apogee</font></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Apogee Therapeutics is a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest I&amp;I markets, including for the treatment of AD, asthma, EoE, Chronic Obstructive Pulmonary Disease (COPD) and other I&amp;I indications. Apogee&#x2019;s antibody programs are designed to overcome limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. Zumilokibart, the company&#x2019;s most advanced program, is being initially developed for the treatment of AD, which is the largest and one of the least penetrated I&amp;I markets, as well as asthma and EoE. With four validated targets in its portfolio, Apogee is seeking to achieve best-in-class efficacy and dosing through monotherapies and combinations of its novel antibodies. Based on a broad pipeline and depth of expertise, the company believes it can deliver value and meaningful benefit to patients underserved by today&#x2019;s standard of care. For more information, please visit </font><font style="color:#467886;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">https://apogeetherapeutics.com</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div><div class="fixed-width-container" style="margin-left:auto;padding-left:0.75in;width:7in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.75in;"><div style="flex-grow:1;"></div><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="page" style="flex-direction:column;overflow:hidden;display:flex;min-height:11in;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.75in;width:7in;box-sizing:content-box;margin-right:auto;padding-right:0.75in;"><div class="absolute-block-container" style="margin-left:-0.75in;z-index:6;position:relative;"></div><div class="absolute-block-container" style="margin-left:-0.75in;z-index:4;position:relative;"></div><div class="absolute-block-container" style="margin-left:-0.75in;z-index:3;position:relative;"></div><div class="absolute-block-container" style="margin-left:-0.75in;z-index:1;position:relative;"><img src="img126220792_0.jpg" alt="img126220792_0.jpg" style="transform:translate(0px, 0px) rotate(0.0deg);z-index:257952768;overflow:hidden;top:0.0729in;left:6.8646in;width:1.5389in;position:absolute;height:0.5333in;"></div><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;">&#160;</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div><div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.75in;width:7in;box-sizing:content-box;margin-right:auto;padding-right:0.75in;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Forward Looking Statements</font></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Certain statements in this press release may constitute &#x201c;forward-looking statements&#x201d; within the meaning of the federal securities laws, including, but not limited to, statements regarding Apogee&#x2019;s expectations regarding: Apogee's plans for its current and future product candidates and programs; the anticipated timing of its clinical trials and clinical trial results, including the APEX Phase 2 Part B 16-week data readout, Phase 3 trials for zumilokibart in AD, APG279 Phase 1b head-to-head interim 24-week data readout against DUPIXENT in AD, and additional Phase 1b asthma trial data; its planned clinical trial designs; its plans for current and future clinical trials, including planned asthma and EoE trials for zumilokibart and advancement of APG273 in respiratory indications; the potential clinical benefit, dosing regimen, safety, PK, PD and efficacy profiles and treatment outcomes of zumilokibart, APG279, APG273, APG990, and APG333, any other product candidates, including combination therapies, and any other potential programs; the pipeline-in-a-product potential and best-in-class profile for zumilokibart; its planned business strategies; its expected timing for future pipeline updates, regulatory decisions, BLA filing for zumilokibart in AD, and potential commercialization; and its expectations regarding the time period over which Apogee's capital resources will be sufficient to fund its anticipated operations. Words such as &#x201c;may,&#x201d; &#x201c;might,&#x201d; &#x201c;will,&#x201d; &#x201c;objective,&#x201d; &#x201c;intend,&#x201d; &#x201c;should,&#x201d; &#x201c;could,&#x201d; &#x201c;can,&#x201d; &#x201c;would,&#x201d; &#x201c;expect,&#x201d; &#x201c;believe,&#x201d; &#x201c;design,&#x201d; &#x201c;estimate,&#x201d; &#x201c;predict,&#x201d; &#x201c;potential,&#x201d; &#x201c;develop,&#x201d; &#x201c;plan&#x201d; or the negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While Apogee believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to Apogee on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in Apogee&#x2019;s filings with the U.S. Securities and Exchange Commission (the SEC)), many of which are beyond Apogee&#x2019;s control and subject to change. Actual results could be materially different. Risks and uncertainties include: global macroeconomic conditions and related volatility, expectations regarding the initiation, progress, and expected results of Apogee&#x2019;s preclinical studies, clinical trials and research and development programs; expectations regarding the timing, completion and outcome of Apogee&#x2019;s clinical trials; the unpredictable relationship between preclinical study results and clinical study results; the applicability of clinical study results to actual outcomes; the timing or likelihood of regulatory filings and approvals; liquidity and capital resources; and other risks and uncertainties identified in Apogee&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 2, 2026, and subsequent disclosure documents Apogee may file with the SEC. Apogee claims the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. Apogee expressly disclaims any obligation to update or alter any statements whether as a result of new information, future events or otherwise, except as required by law.</font></p></div></div><div class="fixed-width-container" style="margin-left:auto;padding-left:0.75in;width:7in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.75in;"><div style="flex-grow:1;"></div><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="page" style="flex-direction:column;overflow:hidden;display:flex;min-height:11in;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.75in;width:7in;box-sizing:content-box;margin-right:auto;padding-right:0.75in;"><div class="absolute-block-container" style="margin-left:-0.75in;z-index:6;position:relative;"></div><div class="absolute-block-container" style="margin-left:-0.75in;z-index:4;position:relative;"></div><div class="absolute-block-container" style="margin-left:-0.75in;z-index:3;position:relative;"></div><div class="absolute-block-container" style="margin-left:-0.75in;z-index:1;position:relative;"><img src="img126220792_0.jpg" alt="img126220792_0.jpg" style="transform:translate(0px, 0px) rotate(0.0deg);z-index:257952768;overflow:hidden;top:0.0729in;left:6.8646in;width:1.5389in;position:absolute;height:0.5333in;"></div><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;">&#160;</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div><div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.75in;width:7in;box-sizing:content-box;margin-right:auto;padding-right:0.75in;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">APOGEE THERAPEUTICS, INC.</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">CONDENSED CONSOLIDATED BALANCE SHEETS</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">(UNAUDITED)</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">(In thousands, except share data)</font></p>
     <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
      <tr style="visibility:collapse;">
       <td style="width:68.76%;box-sizing:content-box;"></td>
       <td style="width:1.04%;box-sizing:content-box;"></td>
       <td style="width:1.04%;box-sizing:content-box;"></td>
       <td style="width:12.5%;box-sizing:content-box;"></td>
       <td style="width:1.04%;box-sizing:content-box;"></td>
       <td style="width:1.04%;box-sizing:content-box;"></td>
       <td style="width:1.04%;box-sizing:content-box;"></td>
       <td style="width:12.5%;box-sizing:content-box;"></td>
       <td style="width:1.04%;box-sizing:content-box;"></td>
      </tr>
      <tr style="height:15pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
       <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Arial;font-kerning:none;min-width:fit-content;">MARCH 31,</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Arial;font-kerning:none;min-width:fit-content;">2026</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Arial;font-kerning:none;min-width:fit-content;">DECEMBER 31,</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Arial;font-kerning:none;min-width:fit-content;">2025</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      </tr>
      <tr style="height:15pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
       <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;font-kerning:none;min-width:fit-content;">Assets</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      </tr>
      <tr style="height:15pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
       <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Current assets:</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      </tr>
      <tr style="height:12.15pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
       <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">$</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">451,797</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">$</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">131,549</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      </tr>
      <tr style="height:15pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
       <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Marketable securities</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">608,088</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">598,643</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      </tr>
      <tr style="height:15pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
       <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Prepaid expenses and other current assets</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">13,912</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">11,166</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      </tr>
      <tr style="height:15pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
       <td style="padding-top:0in;text-indent:20pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Total current assets</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">1,073,797</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">741,358</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      </tr>
      <tr style="height:15pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
       <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Long-term marketable securities</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">198,354</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">172,730</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      </tr>
      <tr style="height:15pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
       <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Property and equipment, net</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">5,280</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">5,688</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      </tr>
      <tr style="height:15pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
       <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Right-of-use asset, net</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">7,707</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">8,687</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      </tr>
      <tr style="height:15pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
       <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Other non-current assets</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">8,516</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">8,671</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      </tr>
      <tr style="height:15pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
       <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Total assets</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">$</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">1,293,654</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">$</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">937,134</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      </tr>
      <tr style="height:15pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
       <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;font-kerning:none;min-width:fit-content;">Liabilities and stockholders' equity</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="border-top:2.25pt double #ffffff03;padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      </tr>
      <tr style="height:15pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
       <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Current liabilities:</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      </tr>
      <tr style="height:15pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
       <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Accounts payable</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">$</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">1,237</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">$</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">1,221</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      </tr>
      <tr style="height:15pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
       <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Lease liability</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">3,138</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">3,504</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      </tr>
      <tr style="height:15pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
       <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Accrued expenses and other current liabilities</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">28,577</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">23,181</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      </tr>
      <tr style="height:15pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
       <td style="padding-top:0in;text-indent:20pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Total current liabilities</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">32,952</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">27,906</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      </tr>
      <tr style="height:15pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
       <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Long-term liabilities:</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      </tr>
      <tr style="height:15pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
       <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Lease liability, net of current</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">4,909</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">5,345</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      </tr>
      <tr style="height:15pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
       <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Total liabilities</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">37,861</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">33,251</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      </tr>
      <tr style="height:15pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
       <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Stockholders' equity:</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="border-top:0.5pt solid #ffffff03;padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      </tr>
      <tr style="height:15pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
       <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Common Stock; $0.00001 par value, 400,000,000 authorized, 75,323,726 issued and 74,882,396 outstanding as of March 31, 2026; 400,000,000 authorized, 69,038,943 issued and 68,401,349 outstanding as of December 31, 2025</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">1</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">1</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      </tr>
      <tr style="height:15pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
       <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Additional paid-in capital</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">1,892,411</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">1,464,561</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      </tr>
      <tr style="height:15pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
       <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Accumulated other comprehensive income (loss)</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">(749)</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">1,080</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      </tr>
      <tr style="height:15pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
       <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Accumulated deficit</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">(635,870</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">)</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">(561,759</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">)</font></p></td>
      </tr>
      <tr style="height:15pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
       <td style="padding-top:0in;text-indent:20pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Total stockholders&#x2019; equity</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">1,255,793</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">903,883</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      </tr>
      <tr style="height:15pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
       <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Total liabilities and stockholders&#x2019; equity</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">$</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">1,293,654</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">$</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">937,134</font></p></td>
       <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      </tr>
     </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div><div class="fixed-width-container" style="margin-left:auto;padding-left:0.75in;width:7in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.75in;"><div style="flex-grow:1;"></div><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="page" style="flex-direction:column;overflow:hidden;display:flex;min-height:11in;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.75in;width:7in;box-sizing:content-box;margin-right:auto;padding-right:0.75in;"><div class="absolute-block-container" style="margin-left:-0.75in;z-index:6;position:relative;"></div><div class="absolute-block-container" style="margin-left:-0.75in;z-index:4;position:relative;"></div><div class="absolute-block-container" style="margin-left:-0.75in;z-index:3;position:relative;"></div><div class="absolute-block-container" style="margin-left:-0.75in;z-index:1;position:relative;"><img src="img126220792_0.jpg" alt="img126220792_0.jpg" style="transform:translate(0px, 0px) rotate(0.0deg);z-index:257952768;overflow:hidden;top:0.0729in;left:6.8646in;width:1.5389in;position:absolute;height:0.5333in;"></div><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;">&#160;</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div><div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.75in;width:7in;box-sizing:content-box;margin-right:auto;padding-right:0.75in;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">APOGEE THERAPEUTICS, INC.</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">(UNAUDITED)</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">(In thousands)</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
     <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:73.0%;border-collapse:separate;margin-right:auto;">
      <tr style="visibility:collapse;">
       <td style="width:64.853%;box-sizing:content-box;"></td>
       <td style="width:1.76%;box-sizing:content-box;"></td>
       <td style="width:1.54%;box-sizing:content-box;"></td>
       <td style="width:12.923%;box-sizing:content-box;"></td>
       <td style="width:1.32%;box-sizing:content-box;"></td>
       <td style="width:1.82%;box-sizing:content-box;"></td>
       <td style="width:1.54%;box-sizing:content-box;"></td>
       <td style="width:12.923%;box-sizing:content-box;"></td>
       <td style="width:1.32%;box-sizing:content-box;"></td>
      </tr>
      <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;font-kerning:none;min-width:fit-content;">THREE MONTHS ENDED MARCH 31,</font></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      </tr>
      <tr style="height:6.9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;font-kerning:none;min-width:fit-content;">2026</font></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;font-kerning:none;min-width:fit-content;">2025</font></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      </tr>
      <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Operating expenses:</font></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      </tr>
      <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
       <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Research and development</font></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">$</font></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">60,819</font></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">$</font></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">46,387</font></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      </tr>
      <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
       <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">General and administrative</font></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">21,953</font></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">16,709</font></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      </tr>
      <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
       <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Total operating expenses</font></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">82,772</font></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">63,096</font></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      </tr>
      <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Loss from operations</font></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">(82,772</font></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">)</font></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">(63,096</font></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">)</font></p></td>
      </tr>
      <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Other income, net:</font></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      </tr>
      <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
       <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Interest income, net</font></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">8,740</font></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">7,840</font></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      </tr>
      <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
       <td style="padding-top:0.01in;text-indent:20pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Total other income, net</font></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">8,740</font></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">7,840</font></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      </tr>
      <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Net loss before taxes</font></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">(74,032</font></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">)</font></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">(55,256</font></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">)</font></p></td>
      </tr>
      <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
       <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Provision for income taxes</font></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">(79</font></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">)</font></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">(83)</font></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      </tr>
      <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Net loss after taxes</font></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">$</font></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">(74,111</font></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">)</font></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">$</font></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">(55,339</font></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">)</font></p></td>
      </tr>
     </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Investor Contact:</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Noel Kurdi</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">VP, Investor Relations</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Apogee Therapeutics, Inc.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0563c1;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Noel.Kurdi@apogeetherapeutics.com</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Media Contact:</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Dan Budwick</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">1AB Media</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0563c1;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">dan@1abmedia.com</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div><div class="fixed-width-container" style="margin-left:auto;padding-left:0.75in;width:7in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.75in;"><div style="flex-grow:1;"></div><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img126220792_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img126220792_0.jpg
M_]C_X  02D9)1@ ! @$ D "0  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $: RX# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M=Q]%(HP *6@:U2?=(****!A1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 W*[O?IG^GU__ %>U,:0AMO0]1W_SZ]*C(8RG'J?7_/7G]:F*
M MN/IS_GH/K40DWS<R?6S6U]++TU?6Y,)<W-S)JS:7G:UGKTU(Y?FX[X!QZ<
MY_I35Q&K,2 0.I_O'H!_G].A)C<'R0J@DXZ-GID8YP<X]#^E&]O(+6W:XF(3
MRXWD8,<*%0;BS#)& HR><=^E*E.KB*BH4XZ<RBVDVW=K3;1WOI^9A6>'PJEC
M,344*<%K)N-EU:U:UM=];72TN>8?&OXI:#\(? 6N^,?$%ZEI!96<I3>Z#?,\
M;+"BY( WRE00.<]J_D!^-OQ>UWXU?$;7O&GB&1[A;R[D6QMI"SFR@B+10M;H
M_P#JQ+&$9\'YATZU]]?\%+/VIIOBAXS/PJ\*ZD#X3\-R21ZY<P2GR;Z:0*\*
MED8HXAF0K@\J0<9/-?E2V\B)WPFW(,N,;QP!R.N1CV!SZ5_7/@_PA#A7!/-\
M70B\1C8.LHM7E!5&I*+MJG_,NCTO9(_S,^DSXFU>-,ZJ9-E.+E'(<DDW4<&T
MJV8X>7*X<NMTXZW3\K6L=%X2\4ZSX%\1:)XLT6ZDM+_0[V*X!A=T>:+S5:1<
MKR?W2E2,]_4<_P!=/[)G[0FA_M"_##0_$]C<QIJEO9):ZG8;U%Q;S(!"IFB!
M)3S61G3.,]<]A_'HJ@SK"Y^5@[$GIMQGJ<]3D\?7//'W%^PE^TM?_ ;XG:99
MWUTT7@SQ+=+;7\99A$&4^5$S D(,2ON!R?8Y%=_B?P92XDRNMFF&IQCC*?-.
ME%*S?NJ3@U\5I+W=?A;35[)/Y[Z-WBEBN >(EEF/KRGD^?S5*I1E/W*%?$SB
MOK%NCC&^LG:VC2Z_ULH2JH#@''S>G7CG\/I_,2,0HR?4#\ZP-!UVQUW2[/5+
M&>*ZM+RWAGAGB8.DB2HKKAUR#P1Z\\<$8K;)5P%R1D=.QQ@]CVXQ_P#7K^/*
MN'J4&Z4XRC5I2<9J2LU)63NGLT]&GV^2_P!4\+C,-C*%&MA:BJ4ZE.,Z<DTU
M*,DG%W5TT[M73>W<<&)/ X^G/3\NM/IJKM[GWIU1&5_7K_F="C9W[W_33\&%
M%%%44%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M K#82"#][MCMC//Y=:17!029"A>@[ =\Y/Y_0_A^'/\ P4W_ ."C;_LN^)?
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M-(Q!"\C"1W( ,FW$?&"<+Q7X1?LP_P#!6:'XJ_MD^-/A?K,MM9?#G6KY-/\
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M]X6X ) !. H/ Q[9.:O:+JM_X:U+2?$6CRF*^T.]BNH+E"5=VCF24?.N,@;
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M/@#XJ:;;O!--)_8&OVL4YT?5X8U$A:&YE5?.EB!4/M&%DX'3%?J__P $-_\
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M",,C*1@\?RZU]4?![]OC]K#X+:G8:OX,^,GB_5+.QD1AI&M:[>W&E2JI'R-
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M[H<XR,?/GDYZ=:;'^T1\:5$,7_"]?B 6,R84^)KHDCS!G@,,C'H,_P Z_P!
M_P#X<O?L.88#X9Z?E2.?[)TW)[\?NOUXXIP_X(P?L//Y4Z_#;3U:(Y4?V5IN
MXD'N/+]0.^>*G_B)G#MOX%7_ ,)ZM^GG_6MP?AOQ!TEA[6_Z":#ZK>U+SU6[
MY59[':?\$9-?U?Q1_P $U?V:]=UW7K_Q-JU]#\6C=ZWJ=RUW?7IMOCK\3[2'
MS[ALM)]FM[>*SCR?DAMXTZ+7Z@5Y7\$_A#X,^ _PQ\,?"CX>Z:FD>#_"@UA=
M'TZ.*.%+<:WK^J^([_$40$:^=J>KWLYVCDRECR37JE?A&<8JGCLWS7&T4XT<
M7F6.Q5*+335/$8JK5IIIZIJ,TK/5;'[MDN%J8')\IP-:2E6P>68#"U9)J2E4
MP^%I4:DE):-.4&[K1[A1117FGIA1110 4444 %%%% $)^^P.!D8Z^@!&>.,'
M'Y]Z;\J J6 +*P5<Y+'&>/7Z#U[#%+(/G#G<%0$L <!\],]_EQZ?CUKC?&_B
MS1/!/A?6?%6N7UO8:;H]C/=3W%S*(XHO)A>15#,<*96&W!/SLV.]7&G4Q%;#
MX6C&4ZF)J0I1A%<TG)\MDDKMWT\NFYS8K$X7"4YXO$U8TZ>&I2JU92:2C2A;
MFDN9I-I).R:WWV/SG_X*D_M>V/[,_P #]6MM(U"*+QUXHM9K+P_;1R@7+ $1
M7CJBD296*5F&W[I&>F:_AUUO5+_Q#J=WJM_=27&IZM=W-[<7,[%Y)&FE:8B5
MR<G;N*)G('3CO]J_\% /VK-9_:M^/?B#Q*UX_P#PAGAN^FM?#-@7?RD W6MT
M\4>YHP)7CWY3[V<G'%?#OF[?L\KPD9$FYMN=N[./SXP>IXK^Y_#3A"GPMDN#
M3IQK9EBXPKXF$XJ*@IQCS<K7O2<;<JNEHM;7LO\ -GQLXTQ7%/%-=PJ\V5X:
MHZ6&A&;<:M.$_=YDG]N.]FU==5:\<CLNQ1G8,B56'SR#')3 &<$@GVQ4JD*^
M!S9D#]T3F121U9<' W8]?I5<!(HY);LLT2LI#QX+(7(VCIQU&<<$9&3GB<-Y
M):65%&0NQ5_B!! R.Y *G(]^1FOTV4Z=.TJ$8RC*:5>+T=.H[<TDE=M+HW9;
M)]#\<JT(XIPP\*?LYRBJRFU:U]%35[KETO;6^EF['VC^P?\ M3:Y^RK\<]#\
M3PW4O_"+ZOJ$%KXEM0[?9MDK);6S.F57Y#*6RPPO)SD5_>EX \::'\1?"6B^
M*]#O;;4M(UJQM[NWN;619(G,D:.Z!URI:-R48=0P]L5_FL"-F-NX<.Z.9'B+
M$K(PR\9=>A:,@%3_  D'MBOZ>?\ @BG^W!]LA;]G/X@ZMB>UV+X+DN9O]</W
MEQ>1EI6Y"#"*(A@$ $=,_P \>.G!4<71P^;9+3E/&TTJN+Y(*TL*O>J2;BFV
M[K9)-7=KW9_4WT?_ !)KX',*7#.;5O9X-6P^#E*7P8Q2C&"5[625]5VVLDS^
MF=DW1LB[DR.BGDX[=<<@8/0 $XQV\L^+_P *]"^,7@;5_!7B&W22QU:W\M]Z
M(S1RHV592X."& )./?DUZK$XF19%&%<93/<8RIYZ;N#U[BI61=V\GG;@#^7O
M_GKC(K^4,)B:^!Q*K86I-5:5>,K-J+HSC:3E%M-RU2T:5TDKH_M['X'"YK@J
MV!S&G#$87$1:J*5I1JQG%)P?E-.VFNBMW7S-^S3^SQX?_9X\#VWA+18(7N$F
MN9;R^55\VY$EQ)+"K2  L(D< =AC@XKZ5V$#*A0HZ#GW!]3SD?D>>U/VX5CT
MRN <@?3D^IX'/<^M(&$:K&W+G)P3GODY/J!UQGGV.:O,<76QV,6*Q5:52I)\
M\I/WG4FK;^36FB2[/5F6395A,FP,<'@*4,/A8.U/#Q2C3A"RT5^B6CN];I+N
M9VIWPTVSN;R1D2.""2XD>0CRXXH(VED+GH#L0D=L]^*_BX_X*[?MH2_M#_%L
M_#/PGJGF?#[P7<7$$D]G-FRU:>0#S4F9&:.8V]S&R@'E2#D$C!_<?_@KC^VL
MG[._PDNO!WA+5H4\>^,8+BSM+>"<?:[6W4*EP71&$J>9!*P'&,<D=37\6-S/
M=7=[<7-VYDEU"YGO9G)+'S;F1IY,D\@EY&R#[]\&OZ4\$N#:52<N(,=3_P!I
MCRRP,)0=O9I\WM'-O1R:2BDOA3=WS,_DCZ1_B)4^K?ZHY6Z<:%6?^VXFG/\
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MCY0/3'\B/PJ;*=E>UG;TVO\ \.0[QC)[N[?WV]>HDA&W/7![8_S]?S[5Y/\
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MK^R7M,0HKVDI\NMV[W5TMK6V\B.-2P4E1T'U& ,=0220<_4<XS4X 7@#C_\
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M&Q=R <*I)XY/[O?M@_\ !*S_ (51^RCX-^(/A&UEOO&OA/33>>,4M$\R2_\
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MX@_\'6H?_':_IIC_ .#:W]E]ER?'/Q$3/\(U"S ^H_<]_K^%._XAJ_V7\_\
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M-)+3M<_TP? _C'1/'/A?1O%&A7UO?:=K%C;7<%Q;R+)$QF@CD=%=20QC9BK
M<@CFNNW+D#(R1D#/)'L.O^3Z5_-K_P $3OVV#XGT)_V=?'NI!M>T'RX_#$\\
MH)OX9/,GN%C>5MTGE1[0=@PO Q7]'J[!M7<68#Y7))."<X!SC'88'(/MFO\
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MJ)!\P]N:*:O"ISMR;DWKK9.UHKLEY=[[F=1>_326BLK=+7_X=_>?GU_P4O\
MV9;;]I_]E;XD> H+6*36VTHZAI5TZ R6K::&OY1"X4LAE6#:=O4D9/-?YI^H
MV&I>%?$EYI$R3Z?K7AK7YXYDE!BGBDTG47\IL'YE$AMPZG )5@:_UJ]0M8[Z
MSO["8 QWUK-;R C(,4\302 Y[E6;VP>M?YV7_!:+]E]OV>?VPM=U/1K![3P=
M\0+A[O2I1'Y<!EM[<2WFUE CR9I&SC)SUY(K]I\(\YK5,3+*:]2^&G*\8REH
MHRE&+LFN5)=D]==#\?\ %+)Z4*,,SI)JIRZQ4?=DXQ;NVOBOV?6WS_K@_P""
M-G[5<7[2W[)?@_\ M2_2\\8^%[5M/UX>9ON+58)OLMD+A68NN^*(;"W;! ('
M'ZZ*655=\$@<G/7CC&>>F">.@R>E?P1?\$"OVK9?@Q^TU-\)M<U1+/PK\4WC
MCMQ/,4@BN-+MI9%&&8(IDE9=N!R??BO[T[:XCNK.*X49\Q%=0,D%),%6'/(*
M$-G(&.@[5\AXBY#7R//\=5I1Y\/C:M2O3E*Z45*3NHVLGRZ.R=[-:-O7ZS@'
M.Z.<9+@</-J%? PI4903^)1C&TG)ZJZMS65D[]=7HJP8 CHV<9]CCMFOQ\_X
M+DC_ (U\_%WITTD_GJ"?K7Z_$E2NU<*%&.@(^H^N0<?_ *_R"_X+CDG_ ()\
M?%WW32!Q[:@G]&/'Z],>+PI"JL_R14HQDWC<.FF[6O)7V^?E?38]CBFI2_U?
MSI5'*$8X+$6:5[VBM^FOEY'^>/X8LXM0\2^&["\^>VU'7].LB$!RD%WJ,,$X
M;/0LCD# P21D\\?W9?"S_@AC^Q9XJ^'_ (3UN_TC5S=:KH>F7]PZQV S/<V<
M$TI4-"207=L9;)SR:_A5\%G'C/P@/^ILT+'XZO:#'X?C[\]?]4SX"(#\(OAZ
M>A/A;1< G!XTVV/OGUQQCOFOW/Q2SK&950P<,#BZF%JS</:N')=IP;:O)2:=
MTK-6;T6VA^*^'N387-Z]:>+PE/%4J?-RJ?,U933ORII:)N^NKN[=ORE7_@@E
M^Q"&$C:-JTS*>!+!8,>.1M_=C']<=J^A?A-_P25_8P^%=W%J&G_"G0-=O+=@
M8KCQ%HUC<2(5[J?*!STYSV_+].54@Y/IV]:>0 =Q[#'M7X5B.*^(JL52J9KB
MJ\):6G.*LFDKIJ*:>]I+7LS]GH\)\/TI>UIY5AJ%2+M>G%KL[ZMVON</X7\#
M^'?!.GPZ1X2T'2M TZW7;;6&F6J6EG&HZYBB"@ ]1QRV.G4]7$TK2E3'M4??
M8CJ1P=IZ#&>/?&2>:O YY%%>'B9U\54A5J5IN4>5RYGSN=K?%*5V]$UJW^9[
MV$PV'P=*5.C2@HSNT[6:NDG9*RV6BMN[ZM(@&0X4J<$')[< ]1W!QQV_*J>L
MV9O]*U&R )^UV%Y;%1U/VBWDB _\>_\ K>FG133:J0J+XH?C9IZZ^1?LDZ<Z
M;=U*_3:Z[;;Z]/U/\R;_ (*@?"NX^#/[<'Q@\.W-I+;V=]J-K=6@DC*A_M-N
MTTA0?*#\TF21VP3BOUY_X-N?CM:^$?BI\2/@MJ%U$K^,3I4NC6\K@/*UG#-<
M3FV0D;MH.9  >ISQD5ZM_P '''[)5_'J'AG]IKPSI;74$/VJ+QG*D+.4WB"T
ML68HO &?XSTSCT/\TG[-?QR\2?LW?&CP3\7_  M?75K?>']5@:X,3LC36=Q+
M'%>(I0@MMMS(#S@=^*_J/#PI\2<"4\/1E&M/ZDN9+WI0G&G%<MEK=32MI>ZT
M=C^9L2Y9'QC4KU8RIQCC7RMIQ4X^UNI)OIR2:W:;>^EE_JP(08_F;(SU[\\^
M_/)]>]/W*!U]N]?+/[)/[27@+]J+X.^%_B;X%UN#4H=5TNT_M"S-S%+/87D$
M*17 GCC+>49)UD*EB"1G.,&OIS!"!@T7F,"5&X[6QDG'.3\OIQGKBOY?QM#Z
MGB*V%Q*G2J49M-.#2ERO1*Z[W6ZOHT[;_P!'X3$?6L/0Q.'E"K3JTX2YE).U
MTF]F[V7I^#M:W+Z_SI20.I ^IJNI+*#M89[$$$?4?R]14G)&"F>@Z'H/U_6L
M5.#BG"2EIM>UOOM_2ZLZXRE?WXV2TT3OT7]:+T) 0<8(.>F#UQUQ2;E'?^O\
MJK.N P0;7.-NXG ]>!@GCKG..,4K@[02%! &[)PIXZGN,=L_XU'MHQ_B1J1\
MXPE)=/Y4^_R]"VVU^Z<9.ZNI^XM?-_/[KOH<-\4?%6F>"O GBKQ1JUY#96.E
MZ%J5PUQ/((XXW2RG>,,S$!=[H% [D],U_EV_M2?$YOC%^T1\3_B7-(77Q!KM
MW$C,>'BTZ:>UC8')!#+'D<XQCKFOZ]_^"\O_  4%TOX6?"Z__9M\"ZQ"_CSQ
MG$T.K2VDZF71X;=TFVS&-O,@^T0.P&1ALX^O\4GAK0-6\8:]HOAG3+.?4==\
M0:S:VMM:6T;2W-VU[>1I<20HHW.(UE:21N<*"37]&^$^2SRO*\9F]=.#K1E7
MH^TNN:FHJ4$[I-<V_5VM?K?^>/$S.(YIF>&RVC)2C0M1K*#YN6JY6FU:]^6V
M^B7?J?U_?\&T?PEGTKP!\4/BE=6<\2>*I--73II$*I<+93S02&(G&[:!@[2<
M=_2OZLH#E!Q@E3C_ #VY]3QBO@K_ ()Q?LVVW[+?[+'P[^'/V=%UB#2EO=0E
M"X<R:F([[8[;5;='YI!SSN!%?>T94*L3<, >!CC)S]03G&#SGKS7XKQ3CGC\
M[S*<G[M3$5>62E=1CSVY87T:ZIZKILS]CX7RZ.$R;+W"3O'#4E*FTDY223E-
MW=T]DU:VNMK._P#.E_P<8_"/4/&?[*MOX_L[:2X_X0"<.[QJ6\M=0O((V+D#
MA=@YYYZ\C-?Q)?#KQ6_@KQ_X,\902F+^P/$&C3/(#@!#?6XFY[$*&!R?K7^G
MY^V%\$-/_:!^ 'Q"^%VHK'(GB#1;IX(Y &#7-C#)<P#:0<GS54#@X)&.:_S"
M_BE\/M>^%/Q$\7?#;Q)ITUEJOA/6[^&XM;J(QN\4MW,UC(4?#'$021"1P,$&
MOVCPMS*EBL@QN1<\5S\\7/F3G[R232\];Z;K770_'_$7 5<+G-+,W!V<HSM]
MEI--IM+=Z)-:J]]&?ZC'[,'Q1TCXQ?!+X?>/-&GCGLM5\/Z>B2Q,&1Y+:TMX
M)L,"03YB-D9&#QBO?,KNQN4;]P7D<_09Y/K^G:OY&?\ @W]_X*%Z7#HTG[*O
MQ/U];?4-->-? $MU<!8[Q)FENKV$&9P7\M2J*(P=O /)%?UJQ7$4_ERQXVE0
MZ$<^6K@,"?0."&7US[U^/\89%B<AS6O3E3<L-*HYTJLHM7IR:;M;3FC)M2Z7
ML]$T?K7!^=T,\RO#^_&&)HTX0G233UC'1ZZZZ.W5>9?:$D'^(MCY6Y4=<\9]
MQT]#ZUP?Q*^'VE_$SP;K?@K69[JUT[7+&:RNI;!Q'.L4T;QML)!&0'; /';I
MC'?QB4 9*L#SDDYP>G//UYSZ9'9Y4'KU]C_G^5?,8?$U*%6.(A5G3<)*5.R2
MY))*S3<;W5EUUVVW^GQ-&->G*C449Q>C3V:LH^7335=]V?SI77_!N%^R#>7E
M[>R>+?B(DU]>75[*L=Y:*JR74[SN%'E9 #.<<_SY@_XAM_V0.I\8?$=1UR;Z
MSQU[YCSTS^6*_HSV*#ZD^O?'N!4;-&05D90.>/U/7/L1BOJEQWQ53I>RP>;8
MJ*^%<O*E&RC9:P=[:+R\SY67!O#TZGML9@:$VY7?.[)J_K%?*^_7J?SFR?\
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MBBB@H\ _:.^!O@_]HOX6^*OA7XTTY+S2_$&FW,:,T:2>7=)%(;9SO!"[9PC
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M/)Q5'_@F9_P0R\7^/=;\/_&']J"QFT7PM9RPW^F^!6C>"\NBK!U.M:?=Q;'
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M"NKR^57F\=Z/I%LTDUW'&J6]K-%! F7\J,/+(SG*C=M[U_79)RK[,%_ESW.
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MA\2/#7PH\&:QXW\57D>GZ/H\'GWMQ(R(%4Y"#<Y5<DD $L/05R'P#^._@?\
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M'E=O:+3W)KUVTY"0P2Q>8J[7C(P6!$>_/S,,Y/SMDY'4G.1S1+((K>Y-P/\
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MC (]AC )'G7P=^&N@_"3P!X=\#>&[..STO0[&&W@A155=XC03/M4*,R2AG)
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MHJ4K6Z1NNVGK;SV/9X1J.ID=9N"C/GJVBF[/W8VO?OWMW\[_ )*?\%M8BO\
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M]UGTU_53]AO]G3PC^SK^SS\/O OA32-/T\'0M/U'49[*".)[NXU&VCO&>=D
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M[GCL>YU,!_#PN&O)PI4.;W9);II/57MTZMA*?.@>)4;]^1YS;<[5B/.TCGD
MCWSS7[+_ /!(#]BP?'GXK?\ "U_%.GR'P'X*G@FLX[J/_1M4N)%95,.Y3',8
M;F,%BO*8R>U?F#\#O@GXO^._Q#T#X<^!K2[U'5=5U"!+DPH\L%G:)*CW!NC&
M"R;K;>4)P"P)/?']\G[(_P"SOX7_ &:_@WX7^'?AVTAA73K&&34;UD19[F\G
M19IA)*BJ)!%/)(BY&5& >17P7C-Q[0R["2R[+*D?K%>+IN,7I3C)6=31MW6R
M;3UW/U/P(\.L3GF<O.:]&4,JIR]I2<HM>TE&47&FDTO=E%MM)O=I:M7^E;&P
M%A;6EI#&JP6D$<,*1C:JQQHL:+@<9"H !V _&KN-R$[2I8?,#P3@X]>..G/O
M4@RHV@Y'\P>ASZ'M[5(HQDGKC@=__K>F?K7\;<\I2E5G+FE*3DM=VW=R];WO
MY^=C_0%12HT\)3@J=*G3C3M%6Y(Q222UMIOYOYD B8'( Q@[N.3QP ,<_D?H
M>E1R0NY8%5:!U*R*PY("D<#!(!Z'(Z=.U706SR./PX_6D9B.WX_Y_P :YE!1
MK/$*6K72VVCT:?KYKUU-U&%.DZ3BI4Y+E:DKIIK6^OE?O<_F(_X+:?L2/+:?
M\-'_  _T@F]L"S>,+>QAYN(Y/+MK65EB7+;%+,Q?@8.,9(K^8^.**(0LI9HP
M75U(!82 $,"/574@C/&/3K_I2?$[P+HOQ*\%>(?!OB"RAO--UVPGM)8I(Q(I
M>2%HXI&# @&.1E8$C'RYZ]/X+/VXOV1_%?[)?Q@U[PCJ=K<GPOK5_/>>&M;,
M;_89(Y7:[F2.X8!3Y?FB)E4?*1LXP /ZY\%./J.8X3^R,SQ%L1A8<E.=62YJ
MF%IJ$4DY-7Y;V6[UBV[R/X3^D1X:8C XEY[D>&?U#$R=7$TZ2T6*F^:<FE=Z
MVT;:VVNKGQ;(S/%./+AYV&X=QDC!S&R9QR.OX#@CI^SG_!,G_@I;J'[,FI:=
M\,?BE=WFJ?#/6IDATV]5VG?0BC$NQ>5DB@C>60;P -R#/;-?C09V \N:!4@E
M^5Y0N,A>C%B._7)XXS55HX\BV5A-: YC8G=L./?@#=P/PK]CS[A;+.*\+5PN
M(A"6&JJ4:+:3M5:]V2=[IK=-.ZLVG=7?X!PAQ=F_!N/I8S!3JT_8RA+%4U>/
M/23BZD7%)-IWUMHNNE[?Z2'PR^-/PW^*^BV.M>!_%FC:_:WL"SQ#3;V*Z=%9
M0Y5Q&3ATSAAV8$=L#U9;J,_Q GTZ'\<\>G'6O\X3X9_M ?&OX.W$4GPX^)&N
MZ(ML01ID.JW%O91CKM2&(@ -U;H3GD\<_7UC_P %7OVR].@CMHO$UK=*BA9+
MFZO+]W;&!N+ENO&2<^PZ9'\W9EX Y[#$UEA,3A7AXSDJ2JUJ3FXI^[=J4+:-
M*S3:_F=S^O,K^E!PO]6PZQ6'QOME3BJW)A:DHJ5E>S5[I/JG;RN?W@&>,]=I
M^I_^M1Y\8Z8'X_\ UJ_A1/\ P5L_;'! A\1:=(@ (87E^<^O1CT/N?Z4G_#V
MS]LS_H/:?_X%W_\ C7C_ /$ ^)[IJI@'M_R^A_<6SGU_I7NCVE])[@KK1QW1
M?[K5\EYKJ_N/[J'N8BQ&W<P Q@G).>BG@]\#WS^))+%\RN1M/..^,]\]^F.M
M?PKM_P %;OVRQTU[3LXY_P!)ONO!_O<Y_ >W:FC_ (*W_MF9YU[3NG4W-^ ,
M8 S\^3QV_'@\TO\ B G$]:7ORP,?9Z1;Q---VMK?G5K[VLU]PZ?TE^%'A:M=
M0QKG"H^2G]6FFXI73V\U=6?=O4_K-_;O_9>\/_M6?!+Q'X0O(K==;MK*6YT"
M]909K>XA4W#1I(59D,YC6,;?O$@'%?P6>-?!/B#X=^+=<\#^)+"ZTO6=%U"Z
MMGL[Z)H;I8HIY4@D:-P&VR1H'5L8*$$8'-?H(_\ P5N_;*+*HUK29$8,)T^T
M7Y=E((P?F /'(XP<\<]?ACXJ?%?Q7\9O&=_X\\3P6@U_5F5M0FA20.3$AC4L
M7)8\<_,>^#S7[-X9<'\6\'UN3$5L'5PT9Q<(_68QY4K<T?B:ES;K:VOE;^??
M&+C_ (1X_P +AL=@Z6*I8RBHJJOJLTVDDW=O7JF_D]#S3>$D221#*\99(PGS
M*2_RL6!ZE>"!Q@CTKZK_ &,OVB]>_97^.GA?QEH]W<_V0]_'%XAL@[8U&&[*
M6Z/-&"%E6U61G!;[@4D $9KY84%3M48*%N>A).2<$8/!QCOVZ485VWM(8[E3
M\CYZ'  .>HZ=/08/K7ZQGF%I9PJ^$Q5*%2EB*$E427/34YKE:OK%I)[;-:/L
M?A^1YCB<KQ.%QV$JSIRPF(I8B@W>$U5IM.-UIKI9]='ZG^DG\(_B3H'Q5\!^
M&O'7AJ]M[_2=<L(IXKFWE66-Y1&GVA R;EW1R%D?'(92#SS7IVY&#%23@#CK
MWQT_^OW^E?RR_P#!$W]M!M.NY_V;_B'K'E03%$\#R7,^(8^'N;U5,A&W>S*
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MY[5UO_!/3X-^,O@7^RK\-?AM\0!;GQ1X>M;V._\ LN_ROWURTB8,@#DA?O9
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MSO5W5I/2][K>VB[*Q_,S^T)_P2__ &D_V;OC=K/[1_\ P3\\36&BGQ!=M?\
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M=T9B95PJE3R1SGMWP3SCL3];#]A#]M3'/[*_[0W_ (8[XH__ #+CCC(S2_\
M#"'[:?\ T:O^T-_X8[XH_P#S,5:SWA]Q]['90Y-+7^T,->^FNE;^O/II'A[B
M&"J0619RZ<VVX?V7C7&[TNKT'V/E*21L#+$O@ A/NC@=/0#OWXSVJLCG?DF7
MG&1G^0)[^^?;%?6W_#"'[:?_ $:O^T-_X8[XH_\ S,4?\,(?MI_]&K_M#?\
MACOBC_\ ,Q67]LY'JGF>5.+^S]?PMNW_ #^[$T>'.(*5*K3_ +!SB3J)J,WE
M>-3IW22:2H6=K7U]-#Y-=R#@-+^'UZ<D?F<\$9YIF_KEYA]<$?H"*^LO^&$/
MVU<D?\,K_M#XYQ_Q8[XH_P!?"X'Z_B3U#^PA^VJ!Q^RQ^T.3_P!D-^*/\O\
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M_.[=N56Z?Y?EV"F;%]Q_GWS3Z*<8N+]V32OLDM%VON-Q3W5_ZN-"@'(S^?\
MG_/T%,VA6R$)/KGCK^7Y_C4M%$H1FTYQ4G'9OI;;^NHDG%6@^1/=+KMO]PTJ
M"<X)/IT_S^=+_#T[=/Z?_7I:*3BY/WI.4=?<:5NENFO9W^X%%).R2;W=M;]_
M^ (O0<8]OQI:**I)))+1)62[)%+;>_GW\PHHHI@%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
?!1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>apge-20260511.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2026-05-08T18:34:19.0948+00:00 -->
<!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://apogeetherapeutics.com/20260511" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:apge="http://apogeetherapeutics.com/20260511" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" namespace="http://fasb.org/us-gaap/2025"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" namespace="http://xbrl.sec.gov/dei/2025"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://apogeetherapeutics.com/20260511/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:roleRef roleURI="http://apogeetherapeutics.com/20260511/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="apge-20260511.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Issuer Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://apogeetherapeutics.com/20260511/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10010.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10130.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10020.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10000.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10090.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10100.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10120.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10110.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10040.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10050.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10060.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10070.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10030.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10080.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10140.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="10190.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="10180.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10210.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10340.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="10170.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10220.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="10160.0" priority="2" use="optional"/>
        </link:presentationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>May 11, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May 11,  2026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Apogee Therapeutics, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001974640<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-41740<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">93-4958665<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">221 Crescent St., Bldg 17, Suite 102b<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Waltham<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02453<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(650)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">394-5230<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.00001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">APGE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="apge-20260511.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apogeetherapeutics.com/20260511/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="apge-20260511.htm">apge-20260511.htm</File>
    <File>apge-20260511.xsd</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>12
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "apge-20260511.htm": {
   "nsprefix": "apge",
   "nsuri": "http://apogeetherapeutics.com/20260511",
   "dts": {
    "inline": {
     "local": [
      "apge-20260511.htm"
     ]
    },
    "schema": {
     "local": [
      "apge-20260511.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 22
   },
   "report": {
    "R1": {
     "role": "http://apogeetherapeutics.com/20260511/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_563d7b72-ba59-4de2-b514-45cfd636ff13",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "h2",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apge-20260511.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_563d7b72-ba59-4de2-b514-45cfd636ff13",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "h2",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apge-20260511.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://apogeetherapeutics.com/20260511/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://apogeetherapeutics.com/20260511/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://apogeetherapeutics.com/20260511/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://apogeetherapeutics.com/20260511/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://apogeetherapeutics.com/20260511/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://apogeetherapeutics.com/20260511/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://apogeetherapeutics.com/20260511/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://apogeetherapeutics.com/20260511/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://apogeetherapeutics.com/20260511/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://apogeetherapeutics.com/20260511/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://apogeetherapeutics.com/20260511/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://apogeetherapeutics.com/20260511/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://apogeetherapeutics.com/20260511/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://apogeetherapeutics.com/20260511/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://apogeetherapeutics.com/20260511/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://apogeetherapeutics.com/20260511/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://apogeetherapeutics.com/20260511/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://apogeetherapeutics.com/20260511/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://apogeetherapeutics.com/20260511/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://apogeetherapeutics.com/20260511/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://apogeetherapeutics.com/20260511/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://apogeetherapeutics.com/20260511/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>13
<FILENAME>0001193125-26-215683-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-26-215683-xbrl.zip
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MHQBN0YFO>-103 !,X.A4]UV3*:ZA<*9-#^XPAK4<=6%T*8MZ"-S?Q>AI@U2
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MM9874'H5VNB;5,'QYN,U18]DRYTP!R#XCXFJ5.BZ23&NTAZ8[(&N+ .@KU2
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M0EU*;'2_=!#@'[[=#3>=5C0/+@@F\Z7&"VIB7A<_^]C\@CW+6PY9C70>4%&
MQ>:0.Q;^8Z-P0510-1%[35B!J+;._[&72.I]$G]D8"!$ RFX3UH>) ?ON\B\
MP>?!9X>RR1^'3_"*78@*1R$E!0UH&[[]]'()K<)BT4718-EF%*,M>,1V-/WD
MV_D.36IIYF "[,XHFO04_JI2!1KOSJ\W[P 1D,?4]A27#20[FDTRRN$8V?RA
M1=&<9\FT%,@()FB!;GF\0 R3K35X,YKLS9M4&U=,C$RHS<<VH5GYFP_SU^R7
M'P/"%EW]L>M1:'@"*:#64U;O:_60ZK,&,H-%B0VG$E+9^S61&K"^TF=+PP$Q
MD>Q!I6_71$GTY5M$+<*ZL\E7K!)N\KB:2?(II(1;<+LF2N' [YLFFW3=Z <;
MB:@MX5<<VP19WLMNZ#UYQ.NHIB*;('I+V(K0_MMR"H9+27 3=$?LS8MNZ"TE
M#U:X["XEG ^OE?* C18*[2%[2RS^1,M"KOFX6DE^83G=E"7O?U#RZ,T&9.Y
M7$Q5'ETKX4O+1M?^?(QH(<M42*W4AM@@E*WI@S5*T/4&Q&=MNRP=6^6E:A5P
MAZ867T'@P,(H9)P+JY7B/5P,339@K(D5)DQK^D)1?$VD>5IGW\X(+NZS*R$U
M4;NEK*/-V2O="'REH>OZB-[S-2V]F4RD5-<6:8;ZDT@W0'>$#)^ROMCNC.]Y
M3B$AN1)2,[4O"V,&\105C'MI6%T4B6T9+ '&TZ]L;J06M&4$5X-JHG=/(3>_
M1\OYF,B89>_71.HOUE@L/>7]WL?1Q.=*R,GC9"1Y&>YQLD_<Z4=8_3;*)L1L
MO45\*EV399+3'_8X?DX;I>0<1SD/,, _ N7?R/0([CXWWTS>NB7?& -PD"K9
MIC/:;1\NM\0X!N @59*5IKA;LHY]O1 ,,+3@;T%U\.=I\*ZT.4:57 M3XBV)
M1]9IA/1.?  <$]S@^K0D.?,S*0GZ/Z& 0]:F(I--/Y.0$!,PT,I'<EFB_4QJ
M E3>+@*W>CVY9'PW(1$8"-  @ZN>OS1#WTV%@ 0A)HA J]>2Y/&["> X( 2J
MGG1I.K^;C@QT:G1$%=0TXK/9_VZ*$BS P:HG7V '[*:"@8(L:@V]+6\;;"DA
M@ $!3@VDUQD(6XI@L*J1P@4A, B100!=HZP*!-6E).]#;,D_* O(!+0[;\9O
M@4"M@WG:HMB2O8 " JORR6G5OMB6>@P$!%*5O#/FQK9])<0 (4B5;*5NQY:L
M(RR0!=N ?9]F[1Y(#5$]^[B&012A&81-#(ZGAF2BXA-*YK+- *(Z4F3&%/D]
M=5"5;B$05%=]F":IRC86Q \U[\$T2;1TNX%@7&S$[ /U]":$/./8>FF2Z-JM
M"8)UN0FS-Q)6-RQ(!>2<E[VA+]W&(%6PZKKLC8B"S0U2&3+#I7DA!5L>L@ID
M%DOSU$LW0F0%%'LLS<M8W1Z1Y9[S5)HGO-&FB:R&]19+\[+D6RFR.B1.2O/$
MUVRPR"HHLU.:E%*T[4*PEYHG31+>=#.&$+"1D;)'@C:7LD\BBC9N".I2MV0?
M",NV<^1)KQ@EC1(OW.01TY9;)$V2EF[]$'Q7K9$FJ99N"!&4B_V1]-F*E,7!
M\IB?^5,7^0,R,FNENJ,ET9F-/(FL170\NG$\NG$\NE$MI>/1C>/1C>/1C4I)
M'H]N'(]N'(]N5$;Z>'3C>'3C>'1C-XK'HQO-']U(Y\+/8C4XD#(\U9A9MOG$
MO0>YK)-0-IY[2EO7VSK_0B&'Y4Z\K_:4C@)\EY$A#J<M[Q+[)"R;N<:ZVB<'
MKJL@_4T:KO-"!(:I<Z)+/W!=)?EW(O+L)8E,Y^W) 'Q1[9C+^!.5ASX*RXV"
M1.>AOR8*W(5D1+Y_$0(+G(E$YNF+D)GV,Q)M'UZ$MC6&2"+WMQ<A-V^?)/H.
M?06WQGM)A'X\<*&K?DWRWCCT:76]X9-H/?1%79E#E*@\]-ZZ:BS%VCJ'OLJ1
M.U.QOI-#'XTR6ROIF8?^0LRY8DFW//0DH\!92UKN*2NW:!M,?J-)[BM9^7_\
MRU>C[]K5<E^V&UU(?25O>"7\2N#S_P%02P,$%     @ 1CFK7-W>%F"I*0
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M(*P9&BLH=D&:"+*-H\ "2A2,5F'A%(Q0,#6EE1HOVYG-@J&,0A-QY.JB5:5
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M9FG;9%4?*0G-(QY%_W_,LV.<F*: =JPZ>88A#!N>QR.</.*^S<GV(MMKPZ&
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MNZ(/R9WK(')/7%FP8YF8ZJ:-K^)J:D01< -GS- ;_\CW0+%0@DK]6#D]H.'
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M-)D&$<S9T5BOH[7,EM8SN\R-8RQZA;6N>FVMWS>UUJ#+@C2)$_@,QL"L&!/
M/EJ1/64M0V.F;G9'#S;='6AZJZ\-VJUBT]V^UM8-K=4>E#1]QFT^&_,H:WT3
M6X5D,5<+BP_(F*B2DMOG:-4F E7$O=7B7B(L$7:_"$MX2V98#8/^Y+9MKLXP
M4"1Q ]_RP%5S'9@>LZW032R/!&Y_U 6E4%2+L#76PUI_8&IM8T\N.R,N)L(2
M80^&L'7&W7:WK76VG/U*9AEM7QV('V3;Z2SUK(3GUZP$,VAYROW8O>',]>%O
MSHZ\((Z/R36JO28A%4TJ^IF4/NJU!YN !N+@:G$P$98(NU^$K2_F&IK>UZM#
MZ,,PQVAKZ.!<(H=/7-NEBFNUT!5T^G-?25]?17[4;76T?F^[NGQO#_=O>#'(
MBR6P(=(3SF\"YSM=0^MUJ+AFE7&^JGM>=/OD!BJWQ84R 7_[ZYVI&X.1JA9
M[A[I(C(#R S81-S6['2TWJ!5E>6HMAU0!UD@PE839(CTA.]K7XN!WM+Z_1JA
M>WV,S"KMWFW%EZN3LU8HLRU*69#S5AFYV@:HF4T34<T)TK''JZW>-RP./^S7
M*M17TX,G-VAIW4Z[.@M"OASY<GM*6()[@OM*P_V@U=.,5JW OCXF:,&U@U\M
MH$^54'C>]V/=O8H4CGN3_80?S/:L.(:9NW?<D4V(URW7YU%>2[6XU6>E2;#$
MJ,U>!UA)]M]S_2+=Q-/CX YGAJ-50P-2W66/269<:%;QIVSWC1QHMD0>OVN
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M>=M %M;!"07MIQV0'RA+^@8KJ5QD$.RA/B(OL,8+4%^#H&]JO9Y9H14A@X!
M?V_(2Z!?XP6H+^AW6YH^V-!1/P+]VNT&;LOIJX=7]R&(8S:)@EGFV04^>73U
MTBU$WIV2M[Z*^6@W[MB!(O5#UU\3+-<3-XB\!,LO@^7=.$P$RU7>&R.OZ%D%
M"Y(ICYCKV\&,:\SG"=4KV/<#R)O2%#4Z'EM174P4)KC8.ES0:?KJ,O/!4+AB
MD77*K]JDS7F!3,WCI&AV5DWR#DB-5'.7EQ: MMDWE5NE]=IZA1:$=MD)\VM
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M92TR,#(V,#4Q,2YX<V102P$"% ,4    " !&.:M<W=X68*DI  !ZU0( #P
M            @ 'K'   87!G92UE>#DY7S$N:'1M4$L%!@     #  , NP
' ,%&      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>apge-20260511_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="apge-20260511.xsd" xlink:type="simple"/>
    <context id="C_563d7b72-ba59-4de2-b514-45cfd636ff13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001974640</identifier>
        </entity>
        <period>
            <startDate>2026-05-11</startDate>
            <endDate>2026-05-11</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="C_563d7b72-ba59-4de2-b514-45cfd636ff13"
      id="F_d0a1e764-9a17-4f00-8f05-631b4565e9d3">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="C_563d7b72-ba59-4de2-b514-45cfd636ff13"
      id="F_61880498-ac0b-405e-af83-3c95a0940da2">0001974640</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="C_563d7b72-ba59-4de2-b514-45cfd636ff13"
      id="F_7db95f53-4e14-4362-b020-2680a1b81e62">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="C_563d7b72-ba59-4de2-b514-45cfd636ff13"
      id="F_13b1fdab-e37e-42f6-8478-cc0408faaca2">2026-05-11</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="C_563d7b72-ba59-4de2-b514-45cfd636ff13"
      id="F_e62ed8a6-c383-456a-a54a-e231451a5a4f">Apogee Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_563d7b72-ba59-4de2-b514-45cfd636ff13"
      id="F_bb188c47-2196-482e-aa24-a048cda6a289">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="C_563d7b72-ba59-4de2-b514-45cfd636ff13"
      id="F_3100d4af-a6ee-4102-8580-0cd1d895d87c">001-41740</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_563d7b72-ba59-4de2-b514-45cfd636ff13"
      id="F_e5231239-9761-4694-a239-294cbc88013e">93-4958665</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_563d7b72-ba59-4de2-b514-45cfd636ff13"
      id="F_156fc5e4-b632-40ae-ae94-681b9b4e097c">221 Crescent St., Bldg 17, Suite 102b</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="C_563d7b72-ba59-4de2-b514-45cfd636ff13"
      id="F_c1881a8b-3e3a-46f8-a399-ef8707fed918">Waltham</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_563d7b72-ba59-4de2-b514-45cfd636ff13"
      id="F_e915b689-9973-4c1b-b372-86fdc652bb47">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_563d7b72-ba59-4de2-b514-45cfd636ff13"
      id="F_7cbd1851-33c7-4283-ba1a-28b8380f99dd">02453</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_563d7b72-ba59-4de2-b514-45cfd636ff13"
      id="F_b40407a7-1fda-4260-8e72-fff126564c95">(650)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_563d7b72-ba59-4de2-b514-45cfd636ff13"
      id="F_2358b1b4-e015-400a-a551-997d197a6878">394-5230</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="C_563d7b72-ba59-4de2-b514-45cfd636ff13"
      id="F_3aaab9bc-9fb4-43e2-a768-42fc66cdac54">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="C_563d7b72-ba59-4de2-b514-45cfd636ff13"
      id="F_9dd67022-5176-40e9-b068-e27b3a226e42">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="C_563d7b72-ba59-4de2-b514-45cfd636ff13"
      id="F_43f47158-4d39-43f6-afaf-5e0e22cb0af7">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="C_563d7b72-ba59-4de2-b514-45cfd636ff13"
      id="F_3e4e1819-96c3-4abe-95e1-1dc4a37a917b">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="C_563d7b72-ba59-4de2-b514-45cfd636ff13"
      id="F_8df06f55-0fcc-417b-8fd3-fc17a3eb4e5a">Common Stock, par value $0.00001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_563d7b72-ba59-4de2-b514-45cfd636ff13"
      id="F_2a877d00-c05f-470d-814b-37b5795b06f1">APGE</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_563d7b72-ba59-4de2-b514-45cfd636ff13"
      id="F_e67cf48a-d427-4747-ade9-7af47c933ad3">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_563d7b72-ba59-4de2-b514-45cfd636ff13"
      id="F_ac35f3a5-56cc-4038-9f5b-25ad952f1f89">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
